Research highlights the potential role of GLP-1 receptor agonists (GLP-1RAs), commonly used for type 2 diabetes and obesity, in managing psoriasis. These agents exhibit both metabolic and immunomodulatory effects, including reduced systemic inflammation, improved insulin sensitivity, and weight loss. Because psoriasis is closely tied to metabolic dysfunction, GLP-1RAs may alleviate disease severity by targeting shared inflammatory pathways. Evidence suggests that these drugs may modulate immune responses by redistributing inflammatory cells like iNKT and γδ T cells, decreasing IL-17 levels, and inhibiting TNF-α signaling.

Clinical studies support their benefit, particularly in patients with both psoriasis and type 2 diabetes, showing rapid improvements in disease severity and inflammatory markers. However, results are mixed in patients without metabolic disease, indicating the therapeutic effect may depend on metabolic status. While not yet standard of care for psoriasis, GLP-1RAs represent a promising adjunctive option for dermatologists treating patients with coexisting metabolic disorders. Ongoing research will be essential to validate their broader use and better define which patient populations are most likely to benefit.

Reference: Fisher J. Exploring the Role of GLP-1 Receptor Agonists in Psoriasis. Dermatology Times. Published May 7, 2025. Accessed July 10, 2025.